statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion...

Cardiff Oncology (CRDF, $5.73) Aroon Indicator entered an Uptrend on April 01, 2024.

Over the last three days, A.I.dvisor has detected that CRDF's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Cardiff Oncology (CRDF, $5.73) entered Uptrend as Momentum indicator ascends above 0 level on Apr 01, 2024

This indicator may be signaling CRDF's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cardiff Oncology (CRDF, $5.36) Aroon Indicator entered an Uptrend on March 28, 2024.

Cardiff Oncology (CRDF, $5.36) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 28, 2024

This is a Bearish indicator signaling CRDF's price could decline from here. Traders may explore shorting the stock or put options...

Cardiff Oncology (CRDF, $5.75) Aroon Indicator entered an Uptrend on March 27, 2024.

Cardiff Oncology (CRDF, $5.4) RSI Indicator left the overbought zone on March 26, 2024

This is a signal that CRDF's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Cardiff Oncology (CRDF, $5.4) Aroon Indicator entered an Uptrend on March 26, 2024.

Cardiff Oncology (CRDF, $5.91) Aroon Indicator entered an Uptrend on March 25, 2024.

Cardiff Oncology (CRDF, $5.85) Aroon Indicator entered an Uptrend on March 22, 2024.

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Cardiff Oncology Inc

Volume	418,426.00
52-Wk High	$6.42
52-Wk Low	$0.94

CRDF Cardiff Oncology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals